Item 2.02 Results of Operations and Financial Condition.

On May 5, 2023, Fulgent Genetics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023. A copy of the Company's press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On May 5, 2023, the Company updated its investor presentation, which is available on the "Investor Relations" section of the Company's website at https://fulgentgenetics.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
  No.     Description
99.1        Press Release of Fulgent Genetics, Inc., dated May 5, 2023
99.2        Corporate Presentation of Fulgent Genetics, Inc.
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses